{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:24:19Z","timestamp":1788845059287,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003693","name":"Korea Institute of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ejmech.2020.112710","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T12:36:07Z","timestamp":1597840567000},"page":"112710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity"],"prefix":"10.1016","volume":"207","author":[{"given":"Ashraf K.","family":"El-Damasy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heewon","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon Hee","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Kyoung","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyochang","family":"Keum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112710_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.112710_bib2","first-page":"62","article-title":"Chronic myeloid leukemia: attributes of break point cluster region-abelson (BCR-ABL)","volume":"3","author":"Rana","year":"2011","journal-title":"J.\u00a0Canc. Res. Exp. Oncol."},{"key":"10.1016\/j.ejmech.2020.112710_bib3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","article-title":"Role of ABL family kinases in cancer: from leukaemia to solid tumours","volume":"13","author":"Greuber","year":"2013","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2020.112710_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR\u2013ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2020.112710_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112710_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.112710_bib7","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112710_bib8","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.112710_bib9","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.112710_bib10","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2020.112710_bib11","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In\u00a0vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112710_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11523-008-0100-y","article-title":"Treatment selection after imatinib resistance in chronic myeloid leukemia","volume":"4","author":"Jabbour","year":"2009","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.ejmech.2020.112710_bib13","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","article-title":"Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia","volume":"14","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112710_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Canc. Cell"},{"key":"10.1016\/j.ejmech.2020.112710_bib15","first-page":"1450","article-title":"Bafetinib, a dual Bcr-Abl\/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia","volume":"11","author":"Santos","year":"2010","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2020.112710_bib16","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112710_bib17","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1021\/jm0102250","article-title":"Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity","volume":"44","author":"Boschelli","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112710_bib18","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1021\/jm901808w","article-title":"A\u00a0type-II kinase inhibitor capable of inhibiting the T315I \u201cgatekeeper\u201d mutant of Bcr-Abl","volume":"53","author":"Choi","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112710_bib19","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1021\/jm100555f","article-title":"Expanding the diversity of allosteric bcr-abl inhibitors","volume":"53","author":"Deng","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112710_bib20","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112710_bib21","doi-asserted-by":"crossref","first-page":"10033","DOI":"10.1021\/jm301188x","article-title":"Design, synthesis, and biological evaluation of 3-(1 H-1, 2, 3-triazol-1-yl) benzamide derivatives as potent pan Bcr-Abl inhibitors including the threonine315\u2192 isoleucine315 mutant","volume":"55","author":"Li","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112710_bib22","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region\u2013Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112710_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Canc. Cell"},{"key":"10.1016\/j.ejmech.2020.112710_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2020.112710_bib25","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1021\/acs.jmedchem.5b01125","article-title":"Development of alkyne-containing pyrazolopyrimidines to overcome drug resistance of Bcr-Abl kinase","volume":"58","author":"Liu","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112710_bib26","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1021\/jm061280h","article-title":"Discovery of N-(4-(3-Amino-1 H-indazol-4-yl) phenyl)-N\u2019-(2-fluoro-5-methylphenyl) urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor","volume":"50","author":"Dai","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112710_bib27","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1016\/j.bmcl.2012.05.125","article-title":"Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors","volume":"22","author":"Ji","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112710_bib28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1021\/ml5000417","article-title":"Discovery of a new series of naphthamides as potent VEGFR-2 kinase inhibitors","volume":"5","author":"Lv","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112710_bib29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejmech.2017.10.008","article-title":"Discovery of novel anti-angiogenesis agents. Part 8: diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors","volume":"141","author":"Sun","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112710_bib30","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bmc.2014.12.002","article-title":"Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold","volume":"23","author":"Jiang","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112710_bib31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejmech.2015.09.034","article-title":"Expanding the structural diversity of Bcr-Abl inhibitors: dibenzoylpiperazin incorporated with 1H-indazol-3-amine","volume":"104","author":"Shan","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112710_bib32","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.bmcl.2015.03.067","article-title":"ABL kinase inhibitory and antiproliferative activity of novel picolinamide based benzothiazoles","volume":"25","author":"El-Damasy","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112710_bib33","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/cmdc.201600224","article-title":"Discovery of a nanomolar multikinase inhibitor (KST016366): a new benzothiazole derivative with remarkable broad-spectrum antiproliferative activity","volume":"11","author":"El-Damasy","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.112710_bib35","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1182\/blood.V87.3.1089.bloodjournal8731089","article-title":"Expression of the hematopoietic growth factor receptor FLT3 (STK-1\/Flk2) in human leukemias","volume":"87","author":"Carow","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2020.112710_bib36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/10428199409056285","article-title":"The expression of FMS, KIT and FLT3 in hematopoietic malignancies","volume":"13","author":"Birg","year":"1994","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejmech.2020.112710_bib37","series-title":"Sulforhodamine B Assay and Chemosensitivity, Chemosensitivity","first-page":"39","author":"Voigt","year":"2005"},{"key":"10.1016\/j.ejmech.2020.112710_bib39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1089\/154065803321537845","article-title":"High throughput ion-channel pharmacology: planar-array-based voltage clamp","volume":"1","author":"Kiss","year":"2003","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ejmech.2020.112710_bib40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112710_bib41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejmech.2016.02.039","article-title":"Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities","volume":"115","author":"El-Damasy","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112710_bib42","series-title":"DTP Human Tumor Cell Line Screen Process","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112710_bib43","series-title":"Discovery Studio Modeling Envi-Ronment","author":"Dassault Syst\u00e8mes BIOVIA","year":"2016"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420306826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420306826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:22:55Z","timestamp":1759328575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420306826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":41,"alternative-id":["S0223523420306826"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112710","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112710"}}